Introduction
Nanomedicine is an expanding field of research that allows the development of nanoparticles (NPs) capable of improving the stability, transport, bioavailability, and specificity during drug delivery to tumor cells. 1 Additionally, NPs may also be useful to increase the sensitivity of different diagnostic techniques, improving the early detection of the disease and the success of the treatment. 2 The first NPs used as vehicles of antitumor drugs were liposomes conjugated with doxorubicin (Dox) or with albumin and paclitaxel (Pac). Currently, there exist a wide diversity of NPs, including some of inorganic nature such as iron oxide and gold NPs. Breast cancer remains the leading cause of cancer death in women, with a frequency that increases with age until menopause. 3 Among the types of breast cancer, ~20%-30% overexpress the proto-oncogene human epidermal growth factor receptor 2 (HER2), and they are characterized as being very invasive. Similarly, tumors in other locations such as colon, stomach, pancreas, bladder, lung, and testicle may also overexpress HER2. 4, 5 At present, much research is focused on the study of the prognostic value of HER2 and the development of new therapies specifically directed against tumors that overexpress this receptor. 6 Depending on the type of breast cancer and its stage, treatment can include surgical resection, radiotherapy, chemotherapy, and hormone therapy. However, there is still a high rate of recurrence and metastasis, due in part to the resistance that tumor cells develop to some drugs. In addition, it is necessary to find more specific drugs that reduce or avoid side effects from conventional chemotherapy, such as, for example, the cardiac dysfunction associated with anthracycline-based therapy. 5, 7 The humanized antibody trastuzumab (Tmab) represented a great advance in the treatment of breast tumors that overexpress HER2. This antibody specifically binds to HER2 and is widely used to treat early, advanced, and metastatic stages of cancer. 2, 8 Tmab interferes with mitogenic signaling induced by the receptor, and its action is highly specific against HER2-overexpressing cells. 9 However, a large proportion of patients develop primary or secondary resistance in the course of the treatment. 10, 11 It has been found that the combined treatment of Tmab and doxorubicin produces a synergistic antitumor effect against HER2-overexpressing breast tumor cells. 12 Unfortunately, there exists evidence that Dox may cause cardiac toxicity, which limits its use. However, Tmab-conjugated NPs loaded with doxorubicin fortify the antitumor effect of the drug, reducing its cardiotoxicity. 13 In this regard, the conjugation of drugs with antibodies that recognize specific antigens of target cells allows the improvement of the specificity of the treatment and, in many cases, reduces the undesired side effects. This strategy has tremendous promise as a new targeted cancer therapy, and a relatively large number of antibody-drug conjugates are already in clinical development.
14 In particular, Tmab conjugated to the cytotoxic agent emtansine was approved by the US Food and Drug Administration in 2013 for the treatment of patients with HER2-positive breast cancer, and it is currently in the market. 15 However, the linkage of the drug to the antibody is far from trivial, and in this context our group has already reported the construction of immunostimulating complexes (ISCOM) functionalized with vinyl sulfone lipid nanocapsules. The reactivity of the vinyl sulfone group toward amine and thiol groups was exploited to obtain ISCOMs functionalized with protein A, the affinity of which for IgG allows the anchoring of an antibody that targets the ISCOMs to specific cells. 16 In this work, we go one step further: ISCOMs functionalized with protein A and loaded with Pac or Dox are conjugated to Tmab and assayed against Tmab-resistant HER2-overexpressing breast cancer cells (HCC1954) and non-overexpressing cells (MCF-7).
Materials and methods Drugs
Paclitaxel (Pac) and doxorubicin hydrochloride (Dox) were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Pac and Dox were solubilized at 1 mg/mL in methanol and water, respectively. Tmab (Herceptin) was purchased from F. Hoffmann-La Roche Ltd (Basel, Switzerland) and was solubilized according to the manufacturer's procedure.
Preparation of the IscOM matrix
The method used to prepare the ISCOMs was adapted from the technique of Rönnberg et al 17 that was previously described by Cruz-Bustos et al. 16 Briefly, to prepare the ISCOM matrix, 30 mg of cholesterol and 30 mg of phosphatidylcholine were mixed and stirred in 2 mL of Milli-Q quality water and 400 mg of detergent MEGA-10. Then, 2 mL of phosphate-buffered saline (PBS, pH 7.4) was mixed with 0.8 mL of this stock solution and 0.6 mL of Quil A (100 mg/mL) and incubated at room temperature under magnetic stirring for 1 hour. The final volume was adjusted to 12 mL by the addition of PBS.
The resulting mixture was dialyzed through Dialysis Membrane-50 (molecular weight cutoff 5,000-10,000) against water for 48 hours at 4°C with at least five changes. ISCOMs were purified by centrifugation in a sucrose gradient (10%, 25%, and 50% sucrose in PBS) at 50,000× g (Beckman Ultracentrifuge, JA 30.50 Ti. Rotor; Beckman Coulter, Brea, CA, USA) at 4°C for 18 hours following Papadopoulou et al 18 and Myschik et al. 19 The pellets containing the ISCOMs were resuspended in 10 mL PBS, dialyzed against water at 4°C for 48 hours, and then lyophilized and stored until used.
Preparation of IscOMs containing paclitaxel or doxorubicin
The drug, 10 mg/mL Pac or Dox, was incorporated into the NP during the preparation of the ISCOMs following the protocol described earlier for the preparation of the ISCOM matrix. The amount of drug incorporated by the ISCOMs was determined spectrophotometrically. An amount of 10 mg aliquot of the final lyophilized product was placed in a solution of 
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IscOMs for selective delivery of cancer drugs chloroform-methanol 50% water and sonicated over five cycles of 2 minutes in order to break the NPs and release the drug. The aqueous phase was measured spectrophotometrically at 230 nm for Pac and at 420 nm for the Dox, and the concentration was estimated from calibration curves. 20, 21 The concentration of drug (DC) inside the ISCOMs and the encapsulation efficiency (EE%) were calculated using the following formulas:
where Wt is the total amount of drug in the NP suspension and Wi is the drug initially added for the preparation of the ISCOMs.
Preparation of IscOMs labeled with nile red
We used nile red (Sigma-Aldrich Co.) as a fluorochrome. The nile red (5 mg/mL) was incorporated into the nanocapsules as described earlier for the drugs.
Functionalization of the IscOMs
ISCOMs were functionalized as reported by Cruz-Bustos et al, 16 and lipid vinyl sulfone (LVS) was synthesized as described by Cruz-Bustos et al and Morales-Sanfrutos et al. 16, 22 In order to link the LVS to the NP, 2 mg/mL of the lipid sulfone was solubilized in methanol and mixed (1:1) with 0.125 mM carbonate buffer (pH 8.3). The solution was then mixed in an orbital shaker with 1 mL of a 2 mg/mL solution of protein A in carbonate buffer at a proportion of 1:1, and it was allowed to react at 4°C for 12 hours. Then, the unreacted vinyl sulfone groups were blocked with a solution of 1 M glycine in carbonate buffer for 4 hours to yield protein A-functionalized ISCOMs that were purified by dialysis and centrifugation as described earlier.
The different types of NPs, ISCOM matrix, ISCOM-paclitaxel (I-Pac), ISCOM-doxorubicin (I-Dox), and ISCOM-nile red (I-NR), were treated as described earlier and then functionalized with Tmab by incubation with a 2 mg/mL antibody solution in carbonate buffer (0.125 mM carbonate, pH 8.3) at a proportion of 1:1 for 12 hours at 4°C and orbital shaking. Unbound Tmab was eliminated by centrifugation (50,000× g, three times).
electron microscopy characterization
An aliquot of each ISCOM preparation was analyzed by transmission electron microscopy (C. Zeiss EM 902; Carl Zeiss Meditec AG, Jena, Germany) by depositing the suspension on carbon-covered meshes stained with 1% phosphotungstic acid.
cell lines and culture conditions
Human breast cancer cell lines MCF-7 and HCC1954 were supplied by the Department of Cell Cultures of the Granada University Scientific Instrumentation Center (Spain). Cells were cultured with Dulbecco's Modified Eagle's Medium (MCF-7) or RPMI-1640 medium (HCC1954) supplemented with 10% heat-inactivated fetal bovine serum, 10 mL/L penicillin-streptomycin 10×, and 2 mM l-glutamine, in a humidified atmosphere of 5% CO 2 at 37°C. Culture media and respective supplements were supplied by Sigma-Aldrich Co. The authors advise that the Ethics Committee of the University of Granada did not require ethics approval for the use of the human cell line in this study as the cell line used is a commercialized ATCC cell line.
Analysis of HER2 expression by flow cytometry
MCF-7 and HCC1954 cells were harvested with PBS-ethylenediaminetetraacetic acid (EDTA), washed with PBS, and resuspended at 1×10 6 cells/mL in a blocking buffer (2% bovine serum albumin and 0.07% EDTA in PBS) for 30 minutes at 4°C. Cells were then centrifuged, washed with PBS, and resuspended in 100 µL of primary antibody against HER2 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA, sc-74241) at the recommended dilution and incubated at 4°C for 30 minutes. Then cells were washed with PBS and incubated at 4°C for 30 minutes with the secondary antibody (Santa Cruz Biotechnology, Inc., sc-2010) at the recommended dilution. Finally, cells were analyzed in a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA), and the results were processed using FlowJo software (v 7.6.5, Tree Star, Inc., Ashland, Oregon, USA). Normal isotype antibody was used for negative controls. 
Uptake studies of nile red-loaded NPs

Results
characterization of the NPs
The structure of the resulting Tmab-conjugated ISCOMs is depicted in Figure 1 . The morphology and the size of the different NPs were checked by transmission electron micro scopy. ISCOM matrix (Figure 2A ) and Tmab-conjugated ISCOMs loaded with Pac ( Figure 2B ), Dox ( Figure 2C ), or nile red ( Figure 2D ) particles showed a homogeneous typical shape of the ISCOM with an average size of 45.42±1.62 nm. The amount of drug carried in delivery systems was 0.17 mg and 0.18 mg per mg of I-Pac-Tmab and I-Dox-Tmab, respectively, and encapsulation efficiency was 21.5% for Pac and 3.6% for Dox.
Analysis of HER2 expression by flow cytometry
The expression levels of the HER2 receptor were analyzed by flow cytometry. Results show that the expression was much lower in MCF-7 cells than in HCC1954 cells, achieving a mean fluorescence intensity of 7.69 ( Figure 3A ) and 92.73 ( Figure 3B) , respectively.
Uptake studies of nile red-loaded IscOM NPs
The ability of HCC1954 and MCF-7 cells to capture ISCOMs after 30 minutes of incubation was evaluated by flow cytometry and fluorescence microscopy ( Figure 4 ). I-NR produced a similar level of fluorescence in both cell lines (Figure 4A and B; mean fluorescence intensity being 6.35 in MCF-7 and 7.01 in HCC1954). However, the uptake of ISCOMs conjugated with Tmab was dependent on the level of overexpression of HER2, being significantly higher for HCC1954 cells the mean fluorescence intensity of which increases from 7.01 to 13.93 16 This figure was made using graphic components obtained from the website: www.somersault1824.com. Abbreviations: NPs, nanoparticles; IscOM, immunostimulating complex; her2, human epidermal growth factor receptor 2.
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IscOMs for selective delivery of cancer drugs ( Figure 4B ). This result was further confirmed by fluorescence microscopy, since cells that do not overexpress HER2 ( Figure 4C ) accumulated lews fluorescence ( Figure 4D ) than those that do it ( Figure 4E and F) .
In vitro cytotoxicity assay
The effect of ISCOMs loaded with Pac or Dox on MCF-7 and HCC1954 cell viability was studied. The following experimental groups were analyzed: drugs alone (Pac or Dox), Tmab-conjugated ISCOM without drugs (I-Tmab), and Tmab-conjugated ISCOMs loaded with Pac or Dox (I-Pac-Tmab, I-Dox-Tmab). Free or encapsulated drugs were used at 0.1 µM (Pac) or 3 µM (Dox). Results are summarized in Figure 5 that show that HCC1954 cells are more sensitive than MCF-7 cells to the drug delivered by Tmab-conjugated ISCOMs.
Cells treated with untargeted Pac ( Figure 5A ) underwent a significant viability reduction, reaching values of 71% in MCF-7 and 41% in HCC1954, compared to the control group. As expected, I-Tmab did not reduce the viability of either cell line, but when the NPs were loaded with paclitaxel (ie, I-Pac-Tmab) only reduced the viability of HCC1954 cells (45%). Similar results were found for Dox ( Figure 5B ). Untargeted Dox reduced the viability of both cell lines (56% in MCF-7 and 44% in HCC1954), I-Tmab did not reduce the viability of either cell line, and targeted Dox (ie, I-Dox-Tmab) affected only HCC1954 cells (56% cell viability).
Discussion
Currently, Tmab therapy is indicated for patients with advanced breast cancer whose tumors overexpress the HER2 receptor. In addition, there are some trials with short-term monitoring showing that the addition of Tmab to chemotherapy halves the risk of relapse. 9, 23, 24 Because of the good results achieved in metastatic patients, this agent has been tested in patients with early HER2+ breast cancer, and, in fact, it is common to include a year of Tmab as part of the 25, 26 More recently, in 2013, Tmab conjugated to the cytotoxic agent emtansine was approved by the US Food and Drug Administration for the treatment of patients with HER2-positive metastatic breast cancer, who previously received Tmab and a taxane, separately or in combination. 15 However, despite this apparent success, there are still issues such as the mechanism of action in vivo, the selection of patients based on drug resistance, the prevention of the resistance to Tmab, and the definition of the best therapy for patients whose tumors progress during treatment that demand 
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IscOMs for selective delivery of cancer drugs further research. 25, 27, 28 In particular, resistance is a major issue since it has been reported that ~70% of the patients who initially responded to Tmab experience progression to metastatic disease within a year. 29 Additionally, both in vitro and in vivo studies have found that the combined treatment of Tmab and Dox produces a synergistic antitumor effect against HER2-overexpressing breast tumor cells, but the cardiotoxicity caused by this drug is an important disadvantage. 12, 24 Nevertheless, some studies have shown that NPs conjugated with Tmab can reduce the adverse effects that traditional chemotherapy involves. 13 In this context, the synthesis of a drug delivery system by coupling Tmab and ISCOM is especially appealing since it combines three synergic effects: 1) the therapeutic effect of the drug and, eventually, of Tmab, 2) the targeting effect of Tmab over breast cancer cells overexpressing HER2, and 3) the high load capacity of ISCOMs. The election of the strategy to couple Tmab to ISCOMs is critical to preserve the functionality of the former, and the good reactivity of vinyl sulfone group toward proteins was envisaged as the tool to obtain the bioconjugate. 30, 31 From a chemical point of view, the coupling relies on the reactivity of the vinyl sulfone group toward Cys, His, and Lys residues, and the fact that according to UniProtKB/Swiss-Prot release 2016_16, Lys is the eighth most frequent amino acid virtually present in any natural protein makes this approach a general coupling strategy. As already reported by our group, the reaction of protein A with LVS promotes the incorporation of protein A to ISCOMs, and the specific interaction between IgGs and protein A can be exploited to further derivatize the ISCOMs with IgGs that act as targeting agents. 16 It is important to highlight that ISCOMs functionalized with protein A are a good example of a flexible drug carrier system that can be loaded with a large number of drugs and coupled to any IgG (Figure 1) . 32 For the purpose of this study, ISCOMs were loaded with Pac (taxane) or Dox (anthracycline), whose efficiency against breast cancer is well established, 12, 33, 34 and have been coupled to Tmab to yield regular vesicles with an average diameter of 45.42 nm (Figure 2) .
The resulting drug delivery systems were assayed on two breast cancer cell lines, MCF-7 and HCC1954. The rationale behind the election of these two cell lines is the different level of expression of HER2, MCF-7 showing a low expression profile whereas HCC1954 overexpressing HER2 and displaying primary resistance to Tmab. Flow cytometry confirmed the functionality of the delivery system and the different level of expression of HER2 by the two cell lines assayed. As expected, the uptake of ISCOMs conjugated with Tmab was dependent on the level of overexpression of HER2, being significantly higher for HCC1954 (Figure 4) , and as a consequence, the drug delivery system was more efficient on HCC1954 cells ( Figure 5 ). These results are in full agreement with those reported by Hendriks et al, 35 who found that the cytotoxic effect of liposomal NPs conjugated with Tmab and loaded with Dox was higher as the cells attain higher levels of the receptor.
In terms of cell viability, the comparison between targeted and nontargeted drug shows that untargeted drugs are more efficient, discouraging the use of these delivery systems in therapy. However, a closer analysis reveals that the targeted drugs are selective toward HCC1954 cells, whereas MCF-7 cells seem to remain unaffected, although the former are resistant to Tmab. Interestingly, disulfide-linked Tmabemtansine also showed high selective activity toward the resistant cells. 36 A possible justification of this result may be that HCC1954 cells overexpress a nonfunctional HER, being resistant to the therapeutic action of Tmab, 37 but that maintains the antigenic properties of recognition, being targetable by Tmab.
Although in the context of drug delivery, the use of LVSs for the functionalization of ISCOMs with antibodies is a feasible strategy and our in vitro studies are promising, in vivo studies are needed to confirm whether ISCOM NPs are therapeutically effective and reduce the side effects associated to Dox and Pac and to study how they are affected by biological and pathological factors. In particular, the structure, physiology, growth, and environment of tumor as well as permeability and renal filtration are important factors that may influence the effectiveness of NPs for drug delivery. 38 Our approach can be implemented to develop novel NPs, and it would be interesting to assay NPs coupled to other targeting antibodies such as bevacizumab (targets vascular endothelial growth factor) 39 and cetuximab 40 or panitumumab 41 (target epidermal growth factor receptor).
Conclusion
We have demonstrated that the combination of ISCOMs and protein A previously functionalized with an LVS yields a versatile nanocarrier that can exploit the reactivity of the vinyl sulfone group toward Cys, His, and Lys to couple to any antibody to deliver drugs to the site of action. In particular, ISCOMs functionalized with Tmab and loaded with Pac or Dox are selective in vitro toward cell lines overexpressing HER2 regardless of the resistance to the antibody.
Although there exist few articles reporting the development of NPs with the same purpose as our study, 35, 42, 43 International Journal of Nanomedicine 2016:11 submit your manuscript | www.dovepress.com
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rodríguez-serrano et al our results are relevant because they may set the groundwork to develop treatments for patients with resistance to the antibody. Although promising in in vitro assays, in vivo studies are necessary to confirm whether they are therapeutically effective and able to reduce the adverse effects associated with Dox and Pac. If successful, these in vivo studies may open a range of possibilities to solve the high cost of health care involving the indiscriminate administration of Tmab, as they could ensure the action of this drug, regardless of whether it is administered to a resistant patient.
